利用细胞免疫标记法,使人们对白血病,特别是急性淋巴细胞性白血病(下简称急淋)的认识提高了一大步。但此法对非淋巴细胞性白血病价值较小,对探测亚临床型白血病不够敏感。若同时作细胞的酶学测定,则可弥补以上的不足,二者相辅相成,可大大提高诊断的准确性和治疗的针对性。现将近十年来白血病酶学临床研究方面的主要进展介绍如下。 The use of cell-mediated immunolabeling has led to a significant step forward in the understanding of leukemia, particularly acute lymphocytic leukemia (hereinafter referred to as acute lymphoblastic leukemia). However, this method is less valuable for non-lymphocytic leukemia and is not sensitive enough to detect subclinical leukemia. If the cell’s enzymatic assay is performed at the same time, it can make up for the above deficiencies, and the two complement each other, which can greatly improve the accuracy of diagnosis and the targeted treatment. The major advances in clinical research on leukemia enzymology for the past decade are described below.